Journal article
The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy
Jessica Michie, Conor Kearney, Edwin D Hawkins, John Silke, Jane Oliaro
Cells | MDPI AG | Published : 2020
DOI: 10.3390/cells9010207
Abstract
One of the hallmarks of cancer cells is their ability to evade cell death via apoptosis. The inhibitor of apoptosis proteins (IAPs) are a family of proteins that act to promote cell survival. For this reason, upregulation of IAPs is associated with a number of cancer types as a mechanism of resistance to cell death and chemotherapy. As such, IAPs are considered a promising therapeutic target for cancer treatment, based on the role of IAPs in resistance to apoptosis, tumour progression and poor patient prognosis. The mitochondrial protein smac (second mitochondrial activator of caspases), is an endogenous inhibitor of IAPs, and several small molecule mimetics of smac (smac-mimetics) have been..
View full abstractRelated Projects (2)
Grants
Awarded by National Health and Medical Research Council
Awarded by National Breast Cancer Foundation
Funding Acknowledgements
This research was funded by the National Health and Medical Research Council, grant number APP1139626 and the National Breast Cancer Foundation, grant number IIRS-18-151.